-
2 months ago | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith
Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy is intended for the treatment of uncontrolled asthma, a condition where asthma symptoms are frequent and disruptive, often due to a virus infection. The mechanism of action of ETH47 aims to prevent the symptoms of uncontrolled asthma at the source by inducing an innate immune response at the point of entry of viruses.
-
2 months ago | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández
The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which is expected to close in late 2025, is intended to absorb Evergreen’s manufacturing capabilities and radiopharmaceutical pipeline.
-
2 months ago | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws
The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic investors. Manas will use the proceeds to scale up its AI technology and drive ahead its drug pipeline programs. Manas AI is one of many startups gunning to address the costly and risky process of drug development, with more than 90% of drug candidates failing to reach the market from the preclinical stage.
-
Jan 17, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith
Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market for clinical trials is expected to grow to over $106 bn by 2032, but stakeholders in this industry face increasingly challenging obstacles, including regulatory hurdles, talent shortages and clinical studies becoming significantly larger, longer, and more complex.
-
Jan 16, 2025 | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws
As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2 billion in 2023 to $73.2 billion in 2028, partly driven by soaring demand for outsourced trial providers. However, clinical trial providers are facing challenges in completing trials efficiently, including long trial durations, increased competition for sites and participants, and complex protocols.
-
Jan 14, 2025 | 
outsourcing-pharma.com | Jonathan Smith
As the Cambridge Healthtech Institute (CHI) celebrates its 16th annual Clinical Ops Executives (SCOPE) Summit in Orlando, Florida, USA, next month, two awards, one for site innovation and another for patient engagement, have released their shortlisted finalists who will battle it out for the winner and runner-up positions.
-
Jan 9, 2025 | 
outsourcing-pharma.com | Jonathan Smith |Rachel Arthur |Liza Laws
As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences is planning to raise 33.95 billion rupees ($397m) in an initial public offering (IPO). Anthem expects to list its shares on the BSE (formerly the Bombay Stock Exchange) and National Stock Exchange of India, according to a draft filing at the end of 2024.
-
Dec 19, 2024 | 
outsourcing-pharma.com | Jonathan Smith
According to the terms of the deal, Gilead will select a set of drug targets and Terray will discover and develop small molecule drugs that bind to them. Gilead has the option to exclusively license compounds in the deal and take on their development and commercialization. In return, Terray will receive an undisclosed upfront payment and milestone payments linked to preclinical, clinical, and sales milestones as well as tiered royalties.
-
Dec 17, 2024 | 
outsourcing-pharma.com | Jonathan Smith
Founded by a team of scientists and healthcare specialists in 2021, Nintx harnesses compounds from Brazil’s world-famous plant ecosystems to develop treatments for complex, multifactorial diseases such as metabolic, immunological, cancer, and brain disorders. The startup unearths disease targets via data-focused technologies that simulate the gastrointestinal system and map out networks of proteins, the human microbiome and plant compounds.
-
Dec 5, 2024 | 
outsourcing-pharma.com | Jonathan Smith |Liza Laws |Almac Group
The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic lateral sclerosis (ALS). As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in addition to undisclosed “near-term” developmental milestone payments, with the whole deal worth up to $480m.
